Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.48 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512956 | 1.00 | CYP3A4 (0.58) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL14367302 | 0.94 | CYP3A4 (0.51) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL15588671 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL15588991 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL16480991 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL16480997 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL16481000 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL16481004 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL15588990 | 0.93 | CYP3A4 (0.59) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 | |
| SCHEMBL19535640 | 0.91 | CYP3A4 (0.54) | CYP3A4CYP2C9PRMT5WDR77BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2552931-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | GILEAD PHARMASSET LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752422-A1 | Stereoselective synthesis of phosphorus containing actives | Gilead Pharmasset LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2552931-A2 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123668-A2 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | CYP3A4 1919/4885CYP2C9 1843/4885PRMT5 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.